1. Home
  2. QFIN vs TBPH Comparison

QFIN vs TBPH Comparison

Compare QFIN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

HOLD

Current Price

$8.49

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$17.03

Market Cap

908.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QFIN
TBPH
Founded
2016
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
908.9M
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
QFIN
TBPH
Price
$8.49
$17.03
Analyst Decision
Buy
Buy
Analyst Count
2
6
Target Price
$22.20
$18.40
AVG Volume (30 Days)
2.9M
351.4K
Earning Date
05-18-2026
05-04-2026
Dividend Yield
12.36%
N/A
EPS Growth
N/A
279.13
EPS
N/A
N/A
Revenue
N/A
$15,386,000.00
Revenue This Year
N/A
$8.46
Revenue Next Year
N/A
N/A
P/E Ratio
$2.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.35
$13.08
52 Week High
$32.69
$21.03

Technical Indicators

Market Signals
Indicator
QFIN
TBPH
Relative Strength Index (RSI) 24.46 56.07
Support Level $8.35 $16.80
Resistance Level $14.28 $17.11
Average True Range (ATR) 0.47 0.06
MACD -0.04 -0.00
Stochastic Oscillator 3.58 25.42

Price Performance

Historical Comparison
QFIN
TBPH

About QFIN Qifu Technology Inc.

Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.

Share on Social Networks: